Emfizatamab

N/A

Report date: 2026/03/19 17:18:27

Base Information

Drug NameEmfizatamab
Drug Alias Nametetraspecific antibody GNC-038GNC-038
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Tetraspecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionAnti-CD19Tumor necrosis factor receptor superfamily member 9 agonistsT cell surface glycoprotein CD3 modulators +[4] 
TargetsTumor necrosis factor receptor superfamily member 9Programmed death-ligand 1T cell surface glycoprotein CD3 +[4] 
Therapy Area/IndicationsSolid tumoursCentral Nervous System LymphomaLupus Erythematosus, Systemic +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesSichuan Baili Pharmaceutical Co LtdSystImmune
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBaili-Bio (Chengdu) Pharmaceutical Co LtdSystImmuneSichuan Baili Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursCentral Nervous System LymphomaLupus Erythematosus, Systemic +[9] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A